Halo Biosciences

Executive Summary

Halo Biosciences is a clinical-stage biotechnology company pioneering first-in-class therapies for inflammatory and fibrotic diseases through modulation of the extracellular matrix (ECM). Founded in 2015 and headquartered in San Diego, the company's lead program targets dysregulated hyaluronan (HA) accumulation, a key driver of pathology in conditions such as pulmonary hypertension (PH) and interstitial lung disease (ILD). By leveraging a deep understanding of ECM biology, Halo aims to address significant unmet medical needs in these progressive, often fatal disorders where current treatments are limited.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 top-line data for lead HA-targeting program in pulmonary hypertension55% success
• H1 2027Initiation of Phase 2 trial in interstitial lung disease70% success
• Q2 2027Series C financing round to support pipeline advancement60% success